Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05906862 Recruiting - Clinical trials for Advanced Solid Tumor

AMT-253 in Patients With Selected Advanced Solid Tumours

Start date: November 6, 2023
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors

NCT ID: NCT05906537 Not yet recruiting - Clinical trials for Advanced Solid Tumors

SKB410 for Injection in Solid Tumors

Start date: June 30, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB410 for injection in patients with advanced solid tumors.

NCT ID: NCT05906524 Not yet recruiting - Other Solid Tumors Clinical Trials

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Start date: April 15, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with Tislelizumab ± Bevacizumab in patients with Advanced HCC and Other Solid Tumors.

NCT ID: NCT05905614 Completed - Clinical trials for Advanced Solid Tumors

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Start date: November 3, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors.

NCT ID: NCT05904730 Enrolling by invitation - Breast Cancer Clinical Trials

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Start date: July 11, 2023
Phase: Phase 1
Study type: Interventional

This Clinical Trial is investigating the potential efficacy of axitinib after genetic testing in BRCA 1/2 Mutation patients, regardless of HER2 expression, who have progressed after at least one line of standard treatment or for whom there is no consensus treatment approach. The use of Axitinib may help physicians plan for more effective patient care in combination with existing treatment protocols.

NCT ID: NCT05904457 Recruiting - Solid Tumors Clinical Trials

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

BRISK
Start date: January 2, 2023
Phase: Phase 2
Study type: Interventional

A national, prospective, multi-center, open-label, single arm phase II trial investigating the efficacy and safety of bevacizumab plus erlotinib in patients with advanced cancers which harbors genomic alterations in Krebs cycle

NCT ID: NCT05904236 Recruiting - Clinical trials for Patients With Advanced Solid Tumors

Safety and Tolerability of Intravenous Administration of ICVB-1042

Start date: May 24, 2023
Phase: Phase 1
Study type: Interventional

Study to evaluate the safety and tolerability of intravenous ICVB-1042

NCT ID: NCT05902845 Recruiting - Neoplasms Clinical Trials

RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL

Start date: April 30, 2023
Phase: Early Phase 1
Study type: Interventional

This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.

NCT ID: NCT05898828 Recruiting - Neoplasms Clinical Trials

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Start date: June 26, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II study to determine the safety and immune response of the H1299 cell lysate vaccine mixed with Montanide(R) ISA-51 VG adjuvant, to be administered on the study in combination with Entinostat and Nivolumab in eligible participants with locally advanced esophageal cancers (EsC) following either neoadjuvant chemoradiation therapy (nCRT) or nCRT and surgery. Phase I of the protocol aims to determine the safe dose of the H1299 lung cancer cell lysate vaccine mixed with Montanide(R) ISA-51 VG adjuvant when it is administered in combination with Entinostat and Nivolumab. Phase II of the protocol will focus on assessing the level of immune response in participants receiving the study intervention when the H1299 cell lysate vaccine with Montanide(R) ISA-51 VG adjuvant is administered at the dose level determined in Phase I.

NCT ID: NCT05898399 Recruiting - Clinical trials for Advanced Solid Tumor

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Start date: June 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Niraparib.